Catabasis Pharmaceuticals, Inc. Names Deirdre Cunnane SVP, General Counsel

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that it has named Deirdre Cunnane, J.D., as senior vice president, general counsel. Ms. Cunnane brings to Catabasis over 25 years of legal counsel experience.

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.